Guggenheim Maintains Buy on CytomX Therapeutics, Raises Price Target to $15

Guggenheim analyst Michael Schmidt has maintained a Buy rating on CytomX Therapeutics (NASDAQ: CTMX) and raised the price target from $10 to $15. This adjustment reflects an optimistic outlook for the company's performance.